uticals, Inc., where he played a central role in commercializing Kos' successful Niaspan® franchise and in building the company from start-up to highly profitable, 1,200 person, fully-integrated enterprise. During his tenure at Kos, Mr. Kiritsy raised approximately $500 million in public equity capital, including Kos' IPO, and spearheaded in excess of 10 major corporate development transactions. In 2005, Fortune Magazine
ranked Kos the fastest growing pharmaceutical company in the U.S. and, in 2006, Kos was acquired by Abbott Laboratories for ~$4 billion.
Prior to Kos, Mr. Kiritsy served as Associate Director of Product Development at the Institute of Molecular Biology where he co-authored several scientific journal articles. Mr. Kiritsy received an A.B. from Bowdoin College in Biology and an M.B.A. from Boston University.
About Avaxia Biologics, Inc.:
Avaxia Biologics is a development-stage company developing oral antibody therapeutics that act locally within the gastrointestinal tract. The antibodies are designed to treat both diseases of the GI tract and metabolic diseases. Using its proprietary antibody platform, Avaxia is developing products for inflammatory bowel disease, GI acute radiation syndrome, celiac disease, oral mucositis, diabetes and obesity.
Page: 1 2 Related biology technology :1
|SOURCE Avaxia Biologics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease2
. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease3
. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis4
. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B5
. CMC Biologics Highlights Technical Acumen at Upcoming Conferences6
. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis7
. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference8
. Adeona Becomes Synthetic Biologics, Inc.9
. Pinnacle Biologics, Inc. Announces the Successful Completion of a Financing Round10
. CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems11
. Bacterin Becomes Premier Founding Sponsor of RMECs New Osteobiologics Registry